GRIP Pharma’s Post

Why is entering the European market so challenging? "It is NOT because of the complexity of Europe, …" Europe has harmonized many of its regulatory standards and procedures, making it easier for biotech companies already familiar with the U.S. regulatory environment to navigate European regulations. Furthermore the unified patent system in Europe offers strong intellectual property protection, which is essential for biotech companies looking to safeguard their innovations. Still, Europe has a diverse range of healthcare systems and reimbursement mechanisms, varying from country to country. However, this challenge can be navigated through local experts or strategic alliances with European biotech/pharma companies. "…, but because of the complexity of the Strategic Options for entering Europe." Ultimately, Europe offers a sizable market for biotech products and services, with a diverse patient population which helps to mitigate the risk of the US-business such as market saturation for rare diseases or increasing P&R restrictions. However, there are many strategic options to enter the European markets such as out-licensing, outsourcing, sequenced entry with own legal entities or combinations of such strategies. Not one solution fits all companies, their specific products and financial set-ups. The complexity of these strategic options requires a well-thought-out strategy and careful planning based on market insights. The Bridge© provides specialized consulting for entry into the European market, independent from 3rd party service providers and based on decades of operational job experience. Follow this link to find a short intro to the concept of The Bridge©: https://lnkd.in/e2HAuEUE Don't hesitate to share this post with anyone who might be interested in the topic.

Incretin mimetic / GLP-1 medications have long been used in #diabetes, but are now getting a lot of attention in #weightloss & in other areas. Mike Gottlieb takes a detailed look, touching on history, the development pipeline, unmet needs, potential new indications, & how companies can evaluate where to play in the space >> https://lnkd.in/gN5u4Nkd #pharmaceutials #biotech #biotechnology #obesitytreatment

Europe's life sciences industry has a history of bringing cutting-edge therapies. However, without increased investment in innovation, the region risks falling behind the rest of the world. As the European Commission debates the first major legislative overhaul of the industry in over 20 years, policymakers and industry leaders face critical decisions. In this video interview, Stefan Oelrich, Member of the Board of Management and President of Pharmaceuticals at Bayer AG shares his thoughts on strengthening Europe's pharmaceutical industry. #OWHealth

Dear colleagues, dear friends, For new commercial-stage Biotech companies – with the US launch coming up or fully underway – sooner than later an urgent question occurs: “How can we maintain revenue growth once our new product reaches its sales plateau in the US market?” Over the past months, our consulting team had many discussions with new commercial-stage US Biotech companies and ran several analyses re. the commercial and financial feasibility of a European market entry: > Licensing-out for Europe is the most often favored option by new commercial-stage US Biotechs > Licensing-out for Europe is in many analysis cases NOT the best option for new commercial-stage US Biotechs > Complexity of European Market Access regulations and Willingness-to-Pay are perceived as major hurdles for pursuing the European market opportunity > Funding of a European market entry (or expansion) is regarded as a major challenge, due to the resource requirements of the initial US Launch > Finding & integrating the necessary (un-biased) expertise (Market Access, Pricing & Reimbursement, Business Model & Go-to-Market, Commercial & Financial Analysis) is difficult and challenging > Entering the European market can offer significant incremental revenue streams & company growth mid- to long-term Based on six defined Strategic Options for a potential European market entry (or expansion), we have developed “The Bridge”, a concept with a structured process and tailored proprietary analytical tools, to analyze and conclude on the optimal European Strategy: from “Out-licensing” to “Market yourself” to “Out-sourcing” to “No entry at all”. Our initial "Financial Acid Test" (FAT), a focused 3-week analysis, will provide first important insights re. the commercial feasibility of a new product for the European market – helping to decide whether or not to move forward with an in-depth analysis of the opportunities, strategies and operational requirements of a potential expansion into the European market. More information about FAT can be found at: 1d3d0b_ca2f470151f4444e8d275ec25d29c089.pdf (bridgeforgrowth.com) Please don’t hesitate to share this post with anyone who might be interested. Greetings, Tom

Europe's life sciences industry has a history of bringing cutting-edge therapies. However, without increased investment in innovation, the region risks falling behind the rest of the world. As the European Commission debates the first major legislative overhaul of the industry in over 20 years, policymakers and industry leaders face critical decisions. In this video interview, Stefan Oelrich, Member of the Board of Management and President of Pharmaceuticals at Bayer AG shares his thoughts on strengthening Europe's pharmaceutical industry. #OWHealth

Europe's life sciences industry has a history of bringing cutting-edge therapies. However, without increased investment in innovation, the region risks falling behind the rest of the world. As the European Commission debates the first major legislative overhaul of the industry in over 20 years, policymakers and industry leaders face critical decisions. In this video interview, Stefan Oelrich, Member of the Board of Management and President of Pharmaceuticals at Bayer AG shares his thoughts on strengthening Europe's pharmaceutical industry. #OWHealth

Pharmaceutical and biotech companies increasingly rely on technology and service providers to accelerate research and development and time to market, while optimizing the commercial success of therapies. This, in turn, creates exciting opportunities for M&A investors in the outsourced services segment. We recently discussed this dynamic subsector with three CEOs, including Paul Brooks of CN Bio , Rasmus Bech Hansen of Airfinity Ltd, and Amir Malka of Bioforum the Data Masters. Access our latest article sharing the drug development trends impacting their growth strategies, the role of M&A in their growth plans, and what an ideal partner looks like for each of their businesses: https://lnkd.in/eUjCuTsa Paul Hepper, Dr Julian Feneley, Andrey Dvorkin

In this article from Life Science Leader, David Stuart discusses his outlook on M&A in the life science sector: M&A Challenges: 👉 Increased antitrust scrutiny 👉 Inflation uncertainty and cost of capital 👉 Geopolitical tensions M&A Opportunities: 👉 The rise of new technologies 👉 Growing demand for personalized medicine 👉 Emerging markets expansion Read more below ⤵️ #MandA #LifeSciences #CDMO

In this article from Life Science Leader, David Stuart discusses his outlook on M&A in the life science sector: M&A Challenges: 👉 Increased antitrust scrutiny 👉 Inflation uncertainty and cost of capital 👉 Geopolitical tensions M&A Opportunities: 👉 The rise of new technologies 👉 Growing demand for personalized medicine 👉 Emerging markets expansion Read more below ⤵️ #MandA #LifeSciences #CDMO